Cell Therapy to Address Treatment Gap Between Pain Management and End-stage Surgery for Chronic Degenerative Diseases
Download the white paper below:
Copyright ©2022 The GID Group
Sign up for our newsletter
Download the white paper below:
As a company committed to proving the promise of regenerative medicine, GID continues to evaluate applications of its SVF-2 cellular implant platform clinically. One such
According to a report in the Proceedings of the National Academy of Sciences, the rate of knee osteoarthritis has more than doubled since 1940, from 6% to
Only two years ago 484 companies were developing regenerative biologic therapies to treat a wide number of diseases and conditions [1]. Today even more companies
Statements in this article are the perspective of the Orlando Medical News Back to All Posts
Statements in this article are the perspective of the San Antonio Business Journal. Back to All Posts
Late-stage biotech GID BIO wins funding from Richard King Mellon Foundation to study regenerative medicine as a potential therapeutic for severe respiratory distress Study to
Denver Business Journal features GID BIO: “Colorado biotech firm’s new cell therapy could eliminate the need for knee replacements” As the total number of confirmed
Statements in this article are the perspective of the Denver Business Journal. Back to All Posts
Bostock joins late-stage biotech as pivotal Phase III trial gets underway for cellular therapy for osteoarthritis of the knee LOUISVILLE, Colo., July 28, 2020 —
Sign up for our newsletter